Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer by Hu, Bang et al.
RESEARCH ARTICLE Open Access
Expression of the phosphorylated MEK5 protein is
associated with TNM staging of colorectal cancer
Bang Hu
1†, Donglin Ren
1†, Dan Su
1, Hongcheng Lin
1, Zhenyu Xian
1, Xingyang Wan
1, Junxiao Zhang
1, Xinhui Fu
1,
Li Jiang
2, Dechan Diao
3, Xinjuan Fan
1, Lei Wang
1* and Jianping Wang
1*
Abstract
Background: Activation of MEK5 in many cancers is associated with carcinogenesis through aberrant cell
proliferation. In this study, we determined the level of phosphorylated MEK5 (pMEK5) expression in human
colorectal cancer (CRC) tissues and correlated it with clinicopathologic data.
Methods: pMEK5 expression was examined by immunohistochemistry in a tissue microarray (TMA) containing 335
clinicopathologic characterized CRC cases and 80 cases of nontumor colorectal tissues. pMEK5 expression of 19
cases of primary CRC lesions and paired with normal mucosa was examined by Western blotting. The relationship
between pMEK5 expression in CRC and clinicopathologic parameters, and the association of pMEK5 expression
with CRC survival were analyzed respectively.
Results: pMEK5 expression was significantly higher in CRC tissues (185 out of 335, 55.2%) than in normal tissues
(6 out of 80, 7.5%; P < 0.001). Western blotting demonstrated that pMEK5 expression was upregulated in 12 of 19
CRC tissues (62.1%) compared to the corresponding adjacent nontumor colorectal tissues. Overexpression of
pMEK5 in CRC tissues was significantly correlated to the depth of invasion (P = 0.001), lymph node metastasis (P <
0.001), distant metastasis (P < 0.001) and high preoperative CEA level (P < 0.001). Consistently, the pMEK5 level in
CRC tissues was increased following stage progression of the disease (P < 0.001). Analysis of the survival curves
showed a significantly worse 5-year disease-free (P = 0.002) and 5-year overall survival rate (P < 0.001) for patients
whose tumors overexpressed pMEK5. However, in multivariate analysis, pMEK5 was not an independent prognostic
factor for CRC (DFS: P = 0.139; OS: P = 0.071).
Conclusions: pMEK5 expression is correlated with the staging of CRC and its expression might be helpful to the
TNM staging system of CRC.
Background
CRC is the third most commonly diagnosed cancer in
males and the second in females, with over 1.2 million
new cancer cases and 608700 deaths estimated to have
occurred in 2008 worldwide [1]. In China, CRC remains
the fourth most common malignant tumor, the fifth
leading cause of cancer-related death and the incidence
continues to increase [2]. At current rates, approxi-
mately 5%-6% of individuals will develop cancer of the
colon or rectum within their lifetime [3]. The survival of
CRC patients is directly associated with the tumor stage
at the time of diagnosis. Patients with distant metastasis
have a poor 5-year survival (12%), while patients with a
localized disease have good prognosis (90%) [4]. How-
ever, currently, few markers besides TNM stage have
been validated as diagnosis criteria in the world wild.
Molecules involved in CRC progression might allow
more accurate diagnosis the stage of CRC, which would
improve efficacy of multimodal therapy and sparing
patients from unnecessary procedures [5].
Mitogen-activated protein kinase kinases (MEKs/
MAPKKs) represent a family of protein kinases
upstream of MAP kinases that play a critical role in reg-
ulating cell proliferation and apoptosis. Mitogen/extra-
cellular signal regulated kinase kinase-5 (MEK5)
encodes a 444-amino-acid protein with an overall 40%
homology to the other MEK proteins [6,7]. MEK5 is
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any medium, provided the original work is properly cited.activated via the dual phosphorylation of its Serine 311
and Threonine 315 by MEKK2,3/Tpl2. Subsequently,
activated MEK5 (pMEK5) specifically activates ERK5,
and then the activated ERK5 phosphorylates substrates
including MEF2, c-Fos, Fra 1, Sap-1, c-Myc and NF-B,
most of which are oncogene [8]. Currently, the MEK5
has been reported as an important protein for sustaining
tumor growth, most likely due to its supportive role in
vasculogenesis and blood vessel homeostasis [9,10].
Moreover, MEK5 has been detected in several tumor
cells or tissues, e.g. including prostate cancer [11-15],
breast cancer [16-21], Hodgkin lymphoma [22,23] and
malignant mesotheliomas [24]. The expression of MEK5
is high in these cancers and is an indicator of poor
prognosis and/or induction of metastasis. However, the
prognostic power has typically been based on total
MEK5 expression and does not consider pMEK5.
In the present study, we have examined the expression
levels of pMEK5 in CRC tissues using immunohisto-
chemistry and Western blot. We explored possible cor-
relations between pMEK5 expression and tumor
progression, to determine its role during tumor
development.
Methods
Patients and tissue specimens
This study was approved by the Institute Research
Medical Ethics Committee of Sun Yat-Sen University.
Written informed consent for using tissue samples was
obtained from all patients. For this study, we per-
formed an immunohistochemical assay of 335 paraffin-
embedded samples of CRC and 80 adjacent normal
mucosa tissue samples collected from patients in the
Department of Gastrointestinal Surgery of the First
Affiliated Hospital, Sun Yat-sen University (Guangz-
hou, P. R. China), between January 2000 and Novem-
ber 2006. Only patients who did not receive
preoperative anticancer treatment were enrolled. Col-
orectal tissues were surgically removed from CRC
patient, normal colorectal mucosa was obtained from
the distal edge of the resection at least 5 cm from the
tumor. Histomorphology of all tumor specimens and
adjacent normal mucosa were confirmed with hema-
toxylin-eosin (H&E) staining. In according with the
International Union against Cancer TNM classification
system, we divided all CRC specimens into four
groups. Clinical parameters such as sex, age at surgery
differentiation grade, lymph node metastasis, distant
metastasis, TNM stage, preoperative CEA level and
preoperative CA19-9 level were collected. All speci-
m e n sw e r ef i x e di n1 0 %f o r m a l i na n de m b e d d e di n
paraffin. Enrolled patients were followed for at least 5
years for survival analysis. After a median follow-up of
62.4 months, 102 (30.4%) of all patients had died. In
addition, for Western blot analysis, we randomly
selected 19 paired samples of CRC and corresponding
adjacent normal tissues from patents that underwent
surgical tissue resection at the Sixth Affiliated Hospital
of Sun Yat-sen University (Guangzhou, P. R. China)
during 2011. Written informed consent was obtained
from each patient before surgery. All excised samples
were obtained within 1 h after the operation to remove
tumor tissue, and were then immediately kept in liquid
nitrogen until further analysis.
Tissue microarray and immunohistochemistry
After screening the H&E-stained slides for optimal
tumor tissue and adjacent tissue at a distance of 5 cm
from the tumor, we constructed TMA slides using the
specimens from the 335 patients and the 80 specimens
of primary CRC paired with normal mucosa in our Tis-
sue Bank. For each specimen, two cores (1 mm dia-
meter) were taken from histologically confirmed normal
adjacent colorectal mucosa to construct the TMAs
using Tissue Array (ALPHELYS, MINIPORE).
Immunohistochemistry was performed using the Envi-
sion System with diaminobenzidine (DAKO Cytomation,
Glostrup, Denmark) according to the manufacture’s pro-
tocol. In brief, antigen retrieval was performed with
citrate buffer (pH 6.0) by heating in a microwave at a
controlled final temperature of 121°C for 15 min. Sec-
tions were incubated overnight at 4°C with the primary
antibody against pMEK5 (phosphor S311 + T315,
Abcam, ab70608, diluted 1:800, HK, China), and then
incubated with the secondary antibody (Envision System,
Dako) for 30 min at room temperature. After rinsing
with PBS three times each for 10 min, the sections were
incubated with 3,3-diaminobenzidine (DAB) liquid for 1
min, counterstained with Mayer hematoxylin, dehy-
drated, and then mounted.
Staining evaluation
For pMEK5 staining, tissue specimens were examined
separately by two independent and experienced patholo-
gists (D. Su and X. J. Fan) under double-blinded condi-
tions without prior clinicopathologic data. Expression of
pMEK5 in CRC was evaluated by scanning the entire
tissue specimen under low magnification (×40) and then
confirmed by high magnification (×400). An immunor-
eactivity score (IRS) system was applied. The staining
intensity for pMEK5 was scored as: 0, negative (color-
less); 1, weak (pallide-flavens); 2, moderate (yellow), and
3 strong (brown). The proportion of stained cells was
also recorded as: 0 (none); 1 (1-25%); 2 (26-50%); 3 (51-
75%); or 4 (76-100%). The intensity and extent scores
were summed to yield a composite score of 0 to 7 for
each specimen[25]. Composite scores of 0-4 were
defined as indicating normal pMEK5 protein expression,
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overexpression.
Western blot analysis
Nineteen pairs of randomly selected CRC patient tissue
specimens and corresponding nontumor specimens were
subjected to Western blot analysis. Total protein was
extracted from frozen colorectal mucosa using the
Whole Protein Extraction Kit (Fermentas, USA). Equal
amounts of protein were separated by electrophoresis
on a 12% SDS polyacrylamide gel and electrotransferred
on a polyvinylidene difluoride (PVDF) membrane (Pall,
Port Washington, New York, USA). The membrane was
blocked with 5% Bovine Serum Albumin (BSA) for 1 h.
The tissues were incubated with primary rabbit polyclo-
nal antibodies against human pMEK5 (1:1000 dilution;
Abcam, HK, China). The immunoreactive signals were
detected with an enhanced chemiluminescence kit
(Amersham Biosciences, Uppsala, Sweden). The proce-
dures were conducted in accordance with the manufac-
turer’s instructions. Levels of b-actin were used to
normalize protein expression.
Statistical analysis
All statistical analyses were carried out using the SPSS
v.17.0 (SPSS, Inc., Chicago, IL). The Chi-square and
Fishers’ exact tests (used when an expected value in
one of the cells was less than 5) for proportionality
were used to analyze the relationship between the
expression of pMEK5 and the clinicopathologic vari-
ables. The survival rates were calculated by the
Kaplan-Meier method, and the differences between the
survival curves were examined by the log-rank test.
Univariate Cox proportional hazards regressions were
applied to estimate the individual hazards ratio (HR)
for the DFS and OS. The significant variables in the
univariate analysis (P <0 . 0 5 )w e r et h e np u ti n t ot h e
multivariate analysis. The HR with 95% confidence
interval was measured to estimate the hazard risk of
individual factors. P values of less than 0.05 were con-
sidered statistically significant.
Results
pMEK5 expression in CRC tissue and normal colorectal
mucosa samples
Immunostaining of pMEK5 in CRC tissues and normal
mucosae was detected as brown-yellow granules in the
cytoplasm (Figure 1). Overexpression of pMEK5 protein
was observed in 186 of the 335 CRC tissues (55.5%;
Figure 1D1/2). In contrast, only 6 of the 80 normal
colorectal samples were upregulated for pMEK5, 74
samples had negative or weakly positive pMEK5 expres-
sion (Figure 1B1/2). Statistical analysis indicated that the
CRC tissue samples exhibited significantly elevated
expression of pMEK5 relative to that observed in the
normal colorectal tissues (P < 0.0001; Figure 1A1/2;
Table 1).
To confirm the expression levels of pMEK5 seen by
immunostaining in the specimens from our TMA, we
examined the expression of pMEK5 protein by Western
blot analysis in 19 randomly selected pairs of CRC
tissues and their matched nontumor colorectal tissues.
In 12 of 19 (62.1%) CRC patients, pMEK5 protein was
upregulated in tumor tissues compared with their adja-
cent nontumor colorectal tissues (Figure 2).
Correlation of pMEK5 protein expression and
clinicopathologic parameters
The relationship between immunohistochemical pMEK5
expression in CRC tissues and various clinicopathologic
characteristics is shown in Table 2. The expression
(staining) of pMEK5 was highly correlated with depth of
invasion (P = 0.001), lymph node metastasis (P < 0.001),
distant metastasis (P < 0.001), preoperative CEA level (P
< 0.001) and TNM stage (P < 0.001). However, pMEK5
expression was not significantly associated with age at
surgery, sex, tumor location, differentiation grade or
preoperative CA19-9 level (P > 0.05; Table 2).
Survival analysis
The mean patient follow-up time was 71.5 months
with a median value of 62.4 months. The 5-year OS
rate of the 335 patients with primary colorectal can-
cer was 69.6%, with 102 deaths observed during the
follow-up period. The 5-year DFS rate was 67.8%.
During the time of follow-up, 82 patients (24.5%)
developed distant metastasis or local recurrence.
According to the univariate analyses, patients whose
localized colorectal tumors overexpressed pMEK5 had
a significantly lower 5-year DFS than patients with
normal pMEK5 expression in their tumors (hazard
ratio: 1.898; 95%CI: 1.264-2.850; P = 0.002; Figure 3A;
Table 3). Similarly, the 5-year OS was also signifi-
cantly lower in CRC patients with pMEK5 overexpres-
sion than CRC patients with normal pMEK5
e x p r e s s i o ni nt h e i rt u m o r s( H R :2 . 1 0 7 ;9 5 % C I :1 . 3 7 6 -
3.227; P < 0.001; Figure 3B; Table 4). In addition,
tumor location (P = 0.018), lymph node metastasis
(P < 0.001), distant metastasis (P < 0.001), TNM stage
(P < 0.001), differentiation grade (P < 0.001), preo-
perative CEA level (P = 0.004) and preoperative
CA19-9 level (P = 0.013) were statistically signifi-
cantly associated with DFS and OS.
Multivariate analysis was performed using the Cox
proportional hazards model for all of the significant
variables in the univariate analysis; however, T stage,
lymph node metastasis, and distant metastasis were
collinear with TNM stage, so we excluded lymph node
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Page 3 of 10Figure 1 Immunohistochemical analysis of the expression of pMEK5 protein. pMEK5 expression was localized within the cytoplasm. A1 and
A2, Elevated pMEK5 expression in the tumor cells of CRC tissue (T) compared with those of adjacent normal mucosa (N); B1 and B2, only weak
staining of pMEK5 was detected in normal colorectal epithelial tissue; C1 and C2, moderately positive expression of pMEK5 in CRC without
distant metastasis; D1 and D2, strongly positive expression of pMEK5 in CRC with distant metastasis (Left panels, ×100, right panels, ×400).
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[26]. The results from the multivariate analyses for DFS
and OS showed that the pMEK5 expression (P >0 . 0 5 )
were not independent prognostic factors for overall sur-
vival (Table 4).
Discussion
Malignant growth is often described as increased cellular
proliferation induced by uncontrolled activation of mito-
genic signaling pathways [27]. The MEK5/ERK5 signal-
ing pathway regulates a wide variety of cellular
processes during development and also plays an impor-
tant role in human malignant diseases[28]. The MEK5/
ERK5 signaling pathway is upregulated in many types of
cancer, including prostate cancer [11-15], breast cancer
[16-21], and oral squamous cell carcinoma [29]. In
metastatic prostate cancer, strong MEK5 expression is
correlated with bony metastases, and less favorable
prognosis is caused by upregulated BMK1-induced acti-
vator protein-1 (AP-1) activity, a consequent induction
of a high level of matrix metallo-protease-9 (MMP-9)
and augmented invasive potential [11]. In oral squamous
cell carcinoma, Sticht and colleagues [29] found that the
high pERK5 expression in oral squamous cell carcinoma
w a sa s s o c i a t e dw i t ha na d v a n c e dt u m o rs t a g ea n dt h e
presentation of lymph node metastases. In breast cancer
cells, the activated oncogene STAT3 binds to the pro-
moter regions of MEK5 and induces transcription, con-
ferring a critical survival signal [17]. Moreover, during
chemotherapeutic-induced apoptosis, overexpression of
MEK5 in breast cancer cells provides a key survival sig-
nal for chemoresistence [30]. These findings suggested
that pMEK5 might be involved in tumor progression
and metastatic events.
Our original studies find that activation of MEK5
(pMEK5) was increased in CRC cases. We examined the
expression of pMEK5 by immunohistochemistry and
western blot, and found that pMEK5 protein expression
was increased in CRC compared with adjacent normal
mucosa from the same individual. Furthermore, we find
that the pMEK5 expression status was significantly cor-
related with progression of CRC.
In this study, we examined the expression of pMEK5
in 335 cases of CRC by immunohistochemistry. pMEK5
was highly expressed with depth of invasion, especially
in T3, T4 carcinomas, but not in T1 and T2 carcinomas
(P = 0.001). Therefore, the depth of invasion is a very
important prognostic factor, suggesting that pMEK5 can
be used as a biomarker to identify subsets of CRC
patients with more aggressive feature.
Another interesting finding was that lymph node
metastases were detected more frequently in CRC
patients with pMEK5 overexpression, when compared
with normal cases of pMEK5 expression (P < 0.001).
The same tendency was observed in distant metastases
(P < 0.001), suggesting that the pMEK5 protein may
play a role in tumor metastasis, which is consistent with
previous studies of prostate cancer [11]. Consistently,
Table 1 pMEK5 expression in normal mucosa and CRC
tissues
Tissue
sample
All
cases
pMEK5 protein P
value
Normal
expression
Overexpression
Normal
mucosa
80 74(92.5%) 6(7.5%) <
0.001
Carcinomas 335 149 (44.5%) 186 (55.5%)
Figure 2 Western blot analysis of pMEK5 protein expression. Western blot analysis of pMEK5 proteins expressed in eight pairs represents
colorectal tumor tissues (T) and their matched adjacent nontumor tissues (N). Expression level was normalized with b-actin.
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Variable Cases pMEK5 protein P value
Normal expression Overexpression
Sex 0.055
Female 158 79(50.0%) 79(50.0%)
Male 177 70(39.5%) 107(60.5%)
Age at surgery, years 0.835
< 65 189 85(45.0%) 104(55.0%)
≥ 65 146 64(43.8%) 82(56.2%)
Tumour location 0.440
Right colon 57 21(36.8%) 36(63.2%)
Left colon 99 45(44.5%) 54(54.5%)
Rectum 179 83(46.4%) 96(53.6%)
pT (invasion depth) 0.001
T1+ T2 62 39(62.9%) 23(37.1%)
T3+ T4 273 110(40.3%) 163(59.7%)
pN (lymph node metastasis) < 0.001
N0 203 113(55.7%) 90(44.3%)
N1-N2 132 36(27.3%) 96(72.7%)
pM (distant metastasis) < 0.001
M0 305 146(47.9%) 159(52.1%)
M1 30 3(10.0%) 27(90.0%)
TNM stage < 0.001
I 49 35(71.4%) 14(28.6%)
II 145 78(53.8%) 67(46.2%)
III 111 33(29.7%) 78(70.3%)
IV 30 3(10.0%) 27(90.0%)
Differentiation grade 0.074
Well 29 17(58.6%) 12(41.4%)
Moderate 278 124(44.6%) 154(55.4%)
Poorly 28 8(28.6%) 20(71.4%)
Preoperative CEA level < 0.001
< 5 ng/ml 190 102(53.7%) 88(46.3%)
≥ 5 ng/ml 145 47(32.4%) 98(67.6%)
Preoperative CA19-9 level 0.251
< 60 U/ml 296 135(45.6%) 161(54.4%)
≥ 60 U/ml 39 14(35.9%) 25(64.1%)
Figure 3 Survival analysis of primary CRC patients (n = 335). Kaplan-Meier estimates of the DFS (A) and OS (B) according to pMEK5
expression in 335 patients. The DFS and OS were significantly lower in patients with pMEK5 overexpression when compared with patients who
had normal pMEK5 expression. P values were calculated using the log-rank test.
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correlation with TNM stage, and pMEK5-overexpression
was significantly higher in cases at advanced stage than
those at early stage.
One of the greatest challenges in colorectal cancer
management is to accurately diagnose the tumor stage
and determine proper adjuvant therapy. In early CRC,
surgery may be all that is required [31,32]. In more
advanced cancer, other treatments, such as chemother-
apy or radiation therapy, may be required [33,34]. So,
detection of the tumor stage seemed to be very impor-
tant. Currently, the TMN staging system of tumors con-
tinues to be the gold standard for clinical stages in
world wild. However, identifying the lymph node metas-
tasis and distant metastasis with TNM staging system is
difficult. For the TNM staging system, the screening of
distant metastasis is primarily determined by imaging
studies (CT, MRI or PET-CT), ultrasound, and by direct
visualization and palpation during operation. These
common examination methods have poor detection of
early distant metastasis, such as CRC patients with less
than 1 cm liver metastasis [35]. Our study found that
pMEK5 could be helpful in the pathological study of
CRC, especially for the classification of different stages
in CRC and early distant metastasis, which would
improve efficacy of multimodal therapy and allocation
of resources, sparing patients from unnecessary
procedures.
Moreover, Kaplan-Meier analysis of the survival curves
showed a significantly worse 5-year disease-free (log-
Table 3 Cox proportional hazards model univariate and multivariate analyses of individual parameters for correlations
with disease-free survival (DFS)
Variable Univariate analysis Multivariate analysis
HR CI(95%) P value HR CI(95%) P value
Sex
Female 1
Male 0.966 0.662-1.409 0.856
Age at surgery, years
<6 5 1
≥ 65 1.228 0.841-1.794 0.287
Tumor location
Colon 1 1
Rectum 1.602 1.083-2.368 0.018 1.874 1.255-2.801 0.001
TNM stage
I-II 1 1
III-IV 2.851 1.933-4.204 < 0.001 2.383 1.572-3.614 < 0.001
pT (invasion depth)
T1-T2 1
T3-T4 1.398 0.822-2.379 0.216
pN (lymph node metastasis)
N0 1
N1-N2 2.351 1.607-3.439 < 0.001
pM (distant metastasis)
M0 1
M1 7.250 4.619-11.38 < 0.001
Differentiation grade
Well and Moderate 1 1
Poorly 3.082 1.830-5.188 < 0.001 2.988 1.746-5.114 < 0.001
Preoperative CEA level
< 5 ng/ml 1 1
≥ 5 ng/ml 1.748 1.196-2.556 0.004 1.192 0.789-1.801 0.405
Preoperative CA19-9 level
< 60 U/ml 1 1
≥ 60 U/ml 1.926 1.146-3.236 0.013 1.779 1.035-3.056 0.037
Phospho-MEK5 protein
Normal expression 1 1
Overexpression 1.898 1.264-2.850 0.002 1.388 0.900-2.141 0.139
Hu et al. BMC Cancer 2012, 12:127
http://www.biomedcentral.com/1471-2407/12/127
Page 7 of 10rank test, P = 0.002) and 5-year overall survival rate
(log-rank test, P < 0.001) for patients whose tumors
overexpressed pMEK5. This suggests that pMEK5 pro-
tein is a biomarker identifying a poor prognosis for
patients with colorectal cancer. However, multivariate
analysis showed that pMEK5 expression is not a bio-
marker for a worse prognosis (DFS: P = 0.139; OS: P =
0.071). Our results demonstrate that pMEK5 expres-
sion was correlated with a worse prognosis, but that
pMEK5 was not an independent prognostic factor for
C R C .T h ek e yr e a s o nm a yb ed u et ot h el a c ko fa d e -
quate cases.
However, this study is retrospective look at the
expression of pMEK5 in the CRC tissue, it is not able to
establish if the expression of the pMEK5 is after CRC
has occurred. And the mechanism of actions for pMEK5
protein is not known and needs further investigation.
Patients with colorectal cancer whose pMEK5 expres-
sion is elevated may require a more powerful adjunctive
therapy and intensive follow-up. Whether pMEK5 has
value clinically as a biomarker for therapeutic
approaches in patients with colorectal cancer should be
followed up with additional appropriately, designed
studies.
Conclusions
In summary, we have provided original data to support
an important role of pMEK5 overexpression in human
CRC. Overexpression of the pMEK5 protein could be
helpful in the classification of different stages in CRC,
Table 4 Cox proportional hazards model univariate and multivariate analyses of individual parameters for correlations
with overall survival (OS)
Variable Univariate analysis Multivariate analysis
HR CI(95%) P value HR CI(95%) P value
Sex
Female 1
Male 1.008 0.683-1.488 0.967
Age at surgery, years
<6 5 1
≥ 65 1.201 0.813-1.773 0.357
Tumor location
Colon 1 1
Rectum 1.560 1.044-2.331 0.030 1.794 1.191-2.701 0.005
TNM stage
I-II 1 1
III-IV 2.884 1.932-4.306 < 0.001 2.287 1.490-3.510 < 0.001
pT (invasion depth)
T1-T2 1
T3-T4 1.373 0.794-2.376 0.257
pN (lymph node metastasis)
N0 1
N1-N2 2.346 1.586-3.469 < 0.001
pM (distant metastasis)
M0 1
M1 7.292 4.601-11.558 < 0.001
Differentiation grade
Well and Moderate 1 1
Poorly 3.206 1.900-5.409 < 0.001 2.853 1.658-4.907 < 0.001
Preoperative CEA level
< 5 ng/ml 1 1
≥ 5 ng/ml 1.904 1.287-2.817 0.001 1.280 0.834-1.964 0.259
Preoperative CA19-9 level
< 60 U/ml 1 1
≥ 60 U/ml 1.911 1.119-3.262 0.018 1.587 0.905-2.782 0.107
Phospho-MEK5 protein
Normal expression 1 1
Overexpression 2.107 1.376-3.227 < 0.001 1.518 0.964-2.388 0.071
Hu et al. BMC Cancer 2012, 12:127
http://www.biomedcentral.com/1471-2407/12/127
Page 8 of 10and it can be used as an adjunct to the TNM stage sys-
tem to assess clinical stage.
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